TGEN Tecogen Inc

Targeted Genetics to Present at Invest Northwest 2004 SEATTLE, March 18 /PRNewswire-FirstCall/ -- Todd E. Simpson, chief financial officer of Targeted Genetics Corporation , will speak at Invest Northwest, a life sciences and CEO investor conferenceon Tuesday, March 23, 2004. Mr. Simpson will provide a corporate overview, along with highlights from the Company's AIDS vaccine, cystic fibrosis and arthritis programs. Presentation details are as follows: What: Invest Northwest 2004 Conference Where: Seattle, WA Bell Harbor Conference Center When: Tuesday, March 23, 2004 11:00 a.m. PST An archived version of Mr. Simpson's slide presentation will be available at http://www.targetedgenetics.com/. Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Companyalso has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies, as well as a promising body of technology for cellular therapy under development by its subsidiary company, CellExSys. For more information about the Company, visit its website at http://www.targetedgenetics.com/. NOTE: This release contains forward-looking statements regarding our product pipeline and clinical trials. These statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from expectations for a number of reasons, including our failure to make progress with our clinical trials, our failure to obtain positive results from our preclinical programs, our failure to obtain regulatory approval and the other risks described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our annual report on Form 10-K for the year ended December 31, 2003. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations. DATASOURCE: Targeted Genetics Corporation CONTACT: Courtney Self of Targeted Genetics Corporation, +1-206-521-7392 Web site: http://www.targetedgenetics.com/

Copyright